JPMorgan Chase & Co. Has Lowered Expectations for Danaher (NYSE:DHR) Stock Price

Danaher (NYSE:DHR) had its target price reduced by investment analysts at JPMorgan Chase & Co. from $275.00 to $245.00 in a research note issued to investors on Wednesday,MarketScreener reports. The firm presently has an “overweight” rating on the conglomerate’s stock. JPMorgan Chase & Co.‘s price objective suggests a potential upside of 37.09% from the stock’s previous close.

A number of other equities research analysts also recently issued reports on DHR. Guggenheim lowered their price target on shares of Danaher from $275.00 to $235.00 and set a “buy” rating on the stock in a report on Wednesday. Deutsche Bank Aktiengesellschaft reissued a “buy” rating on shares of Danaher in a report on Thursday, January 29th. Evercore lowered their price target on shares of Danaher from $254.00 to $225.00 and set an “outperform” rating on the stock in a report on Monday, April 6th. The Goldman Sachs Group lowered their price target on shares of Danaher from $265.00 to $230.00 and set a “buy” rating on the stock in a report on Monday, April 13th. Finally, Argus set a $265.00 price target on shares of Danaher in a report on Wednesday, January 14th. Seventeen investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $242.45.

Danaher Price Performance

Shares of NYSE:DHR opened at $178.72 on Wednesday. The company has a quick ratio of 1.51, a current ratio of 1.87 and a debt-to-equity ratio of 0.33. The firm has a market capitalization of $126.49 billion, a PE ratio of 34.57, a P/E/G ratio of 2.50 and a beta of 0.95. Danaher has a twelve month low of $175.00 and a twelve month high of $242.80. The company has a 50-day moving average price of $196.45 and a two-hundred day moving average price of $214.10.

Danaher (NYSE:DHR) last issued its earnings results on Tuesday, April 21st. The conglomerate reported $2.06 earnings per share for the quarter, topping analysts’ consensus estimates of $1.94 by $0.12. Danaher had a net margin of 14.89% and a return on equity of 10.91%. The firm had revenue of $5.95 billion during the quarter, compared to analyst estimates of $6 billion. During the same quarter last year, the business earned $1.88 earnings per share. The company’s quarterly revenue was up 3.7% on a year-over-year basis. Danaher has set its FY 2026 guidance at 8.350-8.550 EPS. Equities analysts forecast that Danaher will post 8.4 EPS for the current year.

Insiders Place Their Bets

In related news, EVP Gregory M. Milosevich sold 1,320 shares of the firm’s stock in a transaction that occurred on Thursday, February 19th. The shares were sold at an average price of $208.01, for a total value of $274,573.20. Following the sale, the executive vice president directly owned 5,099 shares of the company’s stock, valued at $1,060,642.99. This trade represents a 20.56% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 10.80% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Danaher

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. State Street Corp raised its stake in Danaher by 1.7% in the fourth quarter. State Street Corp now owns 27,681,334 shares of the conglomerate’s stock valued at $6,345,529,000 after purchasing an additional 472,608 shares in the last quarter. Capital International Investors raised its stake in Danaher by 8.9% in the fourth quarter. Capital International Investors now owns 18,246,008 shares of the conglomerate’s stock valued at $4,177,386,000 after purchasing an additional 1,487,768 shares in the last quarter. Price T Rowe Associates Inc. MD grew its position in Danaher by 9.1% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 15,973,240 shares of the conglomerate’s stock valued at $3,656,595,000 after acquiring an additional 1,334,221 shares during the last quarter. Wellington Management Group LLP grew its position in Danaher by 11.2% during the fourth quarter. Wellington Management Group LLP now owns 15,076,796 shares of the conglomerate’s stock valued at $3,451,380,000 after acquiring an additional 1,517,904 shares during the last quarter. Finally, Norges Bank bought a new position in Danaher during the fourth quarter valued at approximately $2,177,106,000. 79.05% of the stock is owned by hedge funds and other institutional investors.

Danaher News Roundup

Here are the key news stories impacting Danaher this week:

• Positive Sentiment: Q1 EPS beat and slight raise to FY EPS range — Danaher beat non‑GAAP EPS estimates ($2.06 vs. consensus) and nudged full‑year adjusted EPS guidance higher, which supports earnings visibility. Earnings Call Highlights
• Positive Sentiment: Bioprocessing momentum and M&A strategy remain drivers — management highlighted strength in bioprocessing and the acquisition pipeline as long‑term growth levers. Q1 Deep Dive
• Neutral Sentiment: Large euro‑denominated senior‑notes offering (~€2.98B net proceeds) — the deal finances operations and transactions but increases liabilities; market reaction depends on how proceeds are used. Notes Offering
• Neutral Sentiment: Masimo acquisition: longer‑term optionality vs. near‑term integration/earnings pressure — analysts note the deal adds strategic upside but may weigh on near‑term returns and capital allocation. Masimo Analysis
• Negative Sentiment: $172.5M shareholder settlement over post‑pandemic demand disclosures — a material cash charge and reputational headwind that increases near‑term litigation/expense risk. Settlement Report
• Negative Sentiment: Revenue miss and Diagnostics softness weighed on the print — core revenue growth was modest and Diagnostics showed weakness (lighter respiratory season at Cepheid), which undercut the EPS beat. Revenue/Segment Notes
• Negative Sentiment: Multiple analyst price‑target cuts (Morgan Stanley, JPMorgan, Wells Fargo, Guggenheim, UBS among others) — downgrades and lower targets increase downside pressure and reduce near‑term analyst support. Morgan Stanley PT Cut

About Danaher

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.